Answers are grounded in this paper and cite their sources.
Laporte J, Biancalana V, Tanner SM, et al. MTM1 mutations in X-linked myotubular myopathy. Hum Mutat. 2000;15:393-409. 2. Beggs AH, Bohm J, Snead E, et al. MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers. Proc Natl Acad Sci USA. 2010;107:14697-14702. 3. Al-Qusairi L, Weiss N, Toussaint A, et al. T-tubule disorganization and defective excitation-contraction coupling in muscle fibers lacking myotubularin lipid phosphatase. Proc Natl Acad Sci USA. 2009;106: 18763-18768. 4. Dowling JJ, Vreede AP, Low SE, Gibbs EM, et al. Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet. 2009;5:e1000372. 5. Amburgey K, Tsuchiya E, de Chastonay S, et al. A natural history study of X-linked myotubular myopathy. Neurology. 2017;89:1355-1364. 6. Beggs AH, Byrne BJ, De Chastonay S, et al. A multicenter, retrospective medical record review of X-linked myotubular myopathy: the RECENSUS study. Muscle Nerve. 2018;57:550-560. 7. Annoussamy M, Lilien C, Gidaro T, et al. X-linked myotubular myopathy: a prospective international natural history study. Neurology. 2019;92:e1852-e1867. 8. Childers MK, Joubert R, Poulard K, et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med. 2014;6:220ra210. 9. Cowling BS, Chevremont T, Prokic I, et al. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. J Clin Invest. 2014; 124:1350-1363. 10. Maani N, Sabha N, Rezai K, et al. Tamoxifen therapy in a murine model of myotubular myopathy. Nat Commun. 2018;9:4849. 11. Mack DL, Poulard K, Goddard MA, et al. Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. Mol Ther. 2017;25:839-854. 12. Elverman M, Goddard MA, Mack D, et al. Long-term effects of systemic gene therapy in a canine model of myotubular myopathy. Muscle Nerve. 2017;56:943-953. 13. Kuntz NL, Sheih P, Smith BK, et al. ASPIRO phase 1/2 gene therapy trial in X-linked myotubular myopathy: preliminary safety and efficacy findings. Neuromuscul Disord. 2018;28(Suppl. 2):S91.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: